IPSEN
Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company markets approximately 20 drugs. It offers pharmaceutical products targeting oncology, endocrinology, and neuromuscular disorders, as well as gastroenterology, cardiovascular, and cognitive disorders. Products The company's products include: Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer. Somatuline and Somatuline Autogel is a sustained... -release formulations for injection of a somatostatin analogue peptide for treating acromegaly. NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used in the treatment of growth failures. Increlex is a recombinant human Insulin-like Growth-Factor-1 for normal growth of bones. Dysport acts to block acetylcholine release for the treatment of motor disorders and various forms of muscular spasticity, including cervical dystonia. Smecta is an oral formulation of pharmaceutical clay used for the treatment of chronic and acute diarrhea in adults and children and in the symptomatic treatment of pain associated with esophageal, gastric, duodenal, or colonic disorders. Forlax is used for the treatment of constipation for adults and children. Tanakan is an oral formulation of EGb 761, extracted from the leaves of the Gingko biloba tree, is used in the treatment of age-related cognitive disorders. As of December 31, 2007, Tanakan is approved for use in approximately 60 countries, including Europe and Asia. Adrovance is used for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency. Adenuric is used for the treatment of chronic hyperuricaemia. Nisis and Nisisco is an oral formulations containing valsartan for treating arterial hypertension. Significant Events On June 15, 2009, Ipsen S.A. and Pharnext SAS announced that they have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth disease, issued from the Pleotherapy technology. History Ipsen S.A. was founded in 1929.
IPSEN
Industry:
Biotechnology Pharmaceutical Product Research
Founded:
1929-01-01
Address:
Boulogne-billancourt, Ile-de-France, France
Country:
France
Website Url:
http://www.ipsen.com
Total Employee:
1001+
Status:
Active
Contact:
(331) 583-3500
Total Funding:
22 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network Domain Not Resolving Apache
Similar Organizations
Active Biotech
Active Biotech is a company with focus on research and development of pharmaceutical products
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Bayer
Bayer is a life science company that specializes in the areas of health care and agriculture.
BioInvent
BioInvent is a research-based pharmaceutical company.
GlaxoSmithKline
GlaxoSmithKline develops and markets products in the areas of pain relief, respiratory, digestive health, oral health, nutrition and skin.
OrganoBalance GmbH
OrganoBalance GmbH develops, produces, and markets medicines used in the treatment of dental and skin bacterial infections.
Phase Holographic Imaging
Phase Holographic Imaging provides time-lapse cytometers for cancer and stem cell researchers in Europe, Asia, and North America.
Reaction Biology
Reaction Biology is an industry leader and innovator specializing in assay services and protein production for early-stage drug discovery
Simbec-Orion Group
Simbec-Orion Group Provides Clinical Development Solutions.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Current Advisors List
Advisor
2019-06-01
Board_member
2018-06-01
Board_member
2016-07-01
Board_member
2008-08-01
Board_member
Board_member
2020-09-01
Current Employees Featured
Elisabeth Vey Analytical Development Leader @ Ipsen
Analytical Development Leader
Philippe Lopes-Fernandes Executive Vice President, Chief Business Officer, Member of the Executive Committee @ Ipsen
Executive Vice President, Chief Business Officer, Member of the Executive Committee
2020-10-01
Paul Murasko Head of Digital Customer Interaction for North America @ Ipsen
Head of Digital Customer Interaction for North America
2020-01-01
Dominique Brard Executive Vice President, Human Resources @ Ipsen
Executive Vice President, Human Resources
Tim Bourque Associate Director of Warehousing & Logistics @ Ipsen
Associate Director of Warehousing & Logistics
2017-04-01
Christophe Jean Executive Vice President, Strategy and Business Development @ Ipsen
Executive Vice President, Strategy and Business Development
Steven Hildemann EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs @ Ipsen
EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs
2020-03-01
Stewart Campbell Executive Vice President & President of North America @ Ipsen
Executive Vice President & President of North America
2021-11-01
Antoine Flochel Directors @ Ipsen
Directors
Nigel Pitt Senior Chemical and Process Development Chemist @ Ipsen
Senior Chemical and Process Development Chemist
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-27 | Epizyme | Epizyme acquired by Ipsen | 247 M USD |
| 2019-02-25 | Clementia Pharmaceuticals | Clementia Pharmaceuticals acquired by Ipsen | 1.3 B USD |
| 2017-04-03 | Merrimack Pharmaceuticals - Assets | Merrimack Pharmaceuticals - Assets acquired by Ipsen | N/A |
| 2015-06-30 | OctreoPharm Sciences | OctreoPharm Sciences acquired by Ipsen | 50 M EUR |
| 2015-02-27 | Canbex Therapeutics | Canbex Therapeutics acquired by Ipsen | 96 M EUR |
| 2013-07-15 | Syntaxin | Syntaxin acquired by Ipsen | 206 M USD |
| 2008-07-05 | Ipsen Pharmaceuticals, Inc. | Ipsen Pharmaceuticals, Inc. acquired by Ipsen | 17.5 M USD |
| 2008-06-05 | Octagen | Octagen acquired by Ipsen | N/A |
| 2008-06-04 | Tercica | Tercica acquired by Ipsen | 373 M USD |
| 2004-03-04 | Sterix Ltd. | Sterix Ltd. acquired by Ipsen | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-18 | BAKX Therapeutics | Ipsen investment in Series A - BAKX Therapeutics | 25 M USD |
| 2021-03-30 | Pyxis Oncology | Ipsen investment in Series B - Pyxis Oncology | 152 M USD |
| 2020-03-02 | Xilio Therapeutics | Ipsen investment in Series B - Xilio Therapeutics | 100.5 M USD |
| 2019-07-17 | Pyxis Oncology | Ipsen investment in Series A - Pyxis Oncology | 22 M USD |
| 2017-02-16 | Rhythm Pharmaceuticals | Ipsen investment in Venture Round - Rhythm Pharmaceuticals | 41 M USD |
| 2017-01-31 | Akkadeas Pharma | Ipsen investment in Funding Round - Akkadeas Pharma | N/A |
| 2015-08-13 | Rhythm Metabolic | Ipsen investment in Series A - Rhythm Metabolic | 40 M USD |
| 2014-02-24 | Thesan Pharmaceuticals | Ipsen investment in Series B - Thesan Pharmaceuticals | 49 M USD |
| 2012-11-27 | Motus Therapeutics | Ipsen investment in Series B - Motus Therapeutics | 8 M USD |
| 2012-06-13 | Motus Therapeutics | Ipsen investment in Series B - Motus Therapeutics | 25 M USD |
Newest Events participated
Key Employee Changes
Official Site Inspections
http://www.ipsen.com Semrush global rank: 1.07 M Semrush visits lastest month: 30.91 K
- Host name: server-3-167-112-97.iad55.r.cloudfront.net
- IP address: 3.167.112.97
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Ipsen"
About Ipsen | Pioneering Biopharmaceutical Company - Global
In 1983, the group created the Fondation Ipsen under the aegis of the Fondation de France, to encourage exchanges between scientists in the field of life sciences. In 1986, the group …See details»
Ipsen: who we are
Ipsen’s products are registered in more than 100 countries. With 5,000 employees working to create value for patients and society around the world, we have global reach while remaining an agile, mid-sized company.See details»
Ipsen - Wikipedia
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employee…See details»
Ipsen - The Org
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - …See details»
Ipsen - Crunchbase Company Profile & Funding
Ipsen invests in R&D to advance scientific discovery and develop new therapeutic solutions across its focus areas. Clinical Trials: Ipsen conducts clinical trials to evaluate the safety and …See details»
Ipsen Org Chart + Executive Team - The Official Board
The organizational chart of Ipsen displays its 66 main executives including David Loew, Aymeric Le Chatelier and Sandra Silvestri. Toggle navigation The Official Board. Search. Search. Search by segment. Sign In. Business E-mail* …See details»
Hello Ipsen - Innovation for patient care
Innovation for patient care. Les patients et la société s’inscrivent au cœur de notre mission. Nous atteignons notre objectif d’améliorer la vie des patients et leur état de santé grâce à une …See details»
Ipsen - LinkedIn
Ipsen | 256,037 followers on LinkedIn. We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease ...See details»
Kaizen Principles: The Ipsen Way - Ipsen Global
At Ipsen, 2025 is the year of Kaizen. Since 2023, Ipsen’s Chief Service Officer John Dykstra and the leadership team have launched several Kaizen kickoff events. The goal: delivering better …See details»
Ipsen Executive Management | Leading Innovation and Growth
Discover Ipsen's executive management team and their role in leading innovation and growth across the organization. Skip to main content. Press shift tab to select search category Media . …See details»
Ipsen: a dynamic, fast-growing specialty care powerhouse - Nature
Ipsen is the first company to test recombinant toxins in preclinical and phase 1 clinical studies 4; the strong internal expertise of its R&D teams has played a critical role in the establishment ...See details»
Ipsen appoints Olivia Brown as Executive Vice-President,
PARIS, FRANCE, March 12 th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global …See details»
Ipsen Group - Devex
Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.909 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial ...See details»
Ipsen Global: Heat treatment furnaces
Powering innovation worldwide. Expertly engineered vacuum and atmosphere furnaces, backed by support for the lifetime of your equipment. With excellence centers in Germany and the …See details»
Member profile: Ipsen Biopharm Ltd | BIA - bioindustry.org
Ipsen also has a well-established Consumer Healthcare business. With total sales close to €2.5 billion in 2020, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial …See details»
Ipsen: who we are - United States
Laboratoires Beaufour created a subsidiary, Ipsen, in 1975, and began to internationalize its activities. In 1976, the company opened a research center in Hopkinton (Massachusetts) in the …See details»
Ipsen Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 …See details»
Ipsen announces issuance of €500 million inaugural Rated
Mar 19, 2025 Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. …See details»
Ipsen (IPN): Company Profile, Stock Price, News, Rankings - Fortune
Fortune 100 Best Companies To Work For Europe 2024 . Ipsen ranks 25 on this year's Fortune 100 Best Companies to Work For Europe list.See details»
Corporate social responsibility | Ipsen Global
We are proud to announce that Ipsen’s rating has reached an all-time high in the 2024 S&P Global Corporate Sustainability Assessment (CSA). Our score has increased by 4 points, from …See details»